Messenger RNA-Based Vaccines Against Infectious Diseases.
In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.
['Alameh|Mohamad-Gabriel|MG|', 'Weissman|Drew|D|', 'Pardi|Norbert|N|']
Vaccines Infectious diseases mRNA Clinical trials LNP SAM